retatrutide eli lilly phase 2 results Lilly's 3 results: 28.3% body weight loss on highest dose Lilly's triple agonist achieves 16.8%

Experimental controls play a central role in mechanistic studies

Most continue normal routines and soon experience more consistent energy, improved mood, and a stronger metabolism

m , EPSC amplitude of POMC neurons that were depolarized in response to GLP-1MK-801 bath application

Preclinical models indicate that the GLP-1 R system has evolved, at least in part, to regulate feeding-related motivation ( Repeated dosing is probably crucial for positive effects in depression and suicidality

Both drugs commonly cause nausea, vomiting, and diarrhea

This triple mechanism of action distinguishes retatrutide from currently approved medicines such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist)